explore
A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.
The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.
advertisement
Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$30
for 3 months, then $39/month
$30 for 3 months Get StartedThen $39/month
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log InNext article： Malaria cases in Florida and Texas: Here’s what you need to know
